Compass Therapeutics (CMPX) Projected to Announce Quarterly Earnings on Wednesday

Compass Therapeutics (NASDAQ:CMPX) will likely be announcing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.12) per share and revenue of $0.23 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 9:30 AM ET.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, analysts expect Compass Therapeutics to post ($0.47) EPS for the current fiscal year and ($0.49) EPS for the next fiscal year.

Compass Therapeutics Trading Down 2.4%

NASDAQ:CMPX opened at $0.77 on Tuesday. The firm has a market capitalization of $138.22 million, a PE ratio of -1.92 and a beta of 1.02. The stock has a 50 day moving average of $1.43 and a 200-day moving average of $3.21. Compass Therapeutics has a 52 week low of $0.73 and a 52 week high of $6.88.

Analyst Ratings Changes

Several analysts recently issued reports on CMPX shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Compass Therapeutics in a report on Wednesday, September 23rd. Lifesci Capital downgraded Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 22nd. Citizens Jmp dropped their target price on Compass Therapeutics to $4.00 and set a “market outperform” rating on the stock in a research report on Wednesday, September 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Thursday, October 15th. Finally, Wedbush set a $4.00 target price on Compass Therapeutics in a research note on Wednesday, September 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $10.25.

About Compass Therapeutics

Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving immune responses in patients with cancer.

Its lead product candidate, CTX-471, is a fully human monoclonal antibody designed to activate CD137, also known as 4-1BB. CD137 is a co-stimulatory receptor found on immune cells, including T cells and natural killer cells.